Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967567 | 0.82 | TDP1 (0.48) | PARP1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1712196 | 0.81 | GSK3B (0.48) | ERCC5FEN1GAATSHRMEN1 | |
| SCHEMBL1712729 | 0.80 | TDP1 (0.47) | ERCC5FEN1MEN1KMT2AALDH1A1 | |
| SCHEMBL220454 | 0.79 | ERCC5 (0.49) | ERCC5FEN1PARP1GAAMEN1 | |
| SCHEMBL1882737 | 0.78 | CYP3A4 (0.53) | ERCC5FEN1PARP1GAATSHR | |
| SCHEMBL6499526 | 0.76 | ERCC5 (0.53) | ERCC5FEN1PARP1GAAMEN1 | |
| SCHEMBL9991305 | 0.76 | ERCC5 (0.53) | ERCC5FEN1PARP1GAAMEN1 | |
| SCHEMBL4888739 | 0.76 | GRM5 (0.54) | ERCC5FEN1PARP1GAAMEN1 | |
| SCHEMBL3869644 | 0.76 | ERCC5 (0.56) | ERCC5FEN1PARP1GAAMEN1 | |
| SCHEMBL10514397 | 0.75 | GAA (0.50) | GAATSHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2344460-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Galapagos N.V. (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | ERCC5 3695/4885FEN1 4185/4885PARP1 4004/4885 |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | ERCC5 3713/4885FEN1 4039/4885PARP1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.